Voclosporin

Voclosporin differs from cyclosporine A by a single carbon extension with a functional group on the amino acid-1 side chain, which modifies its binding to calcineurin and shifts its metabolism. It forms the same cyclophilin complex and blocks calcineurin-mediated NFAT dephosphorylation, cutting IL-2 transcription and T-cell activation. The practical difference is threefold: greater potency at lower exposure, faster metabolism producing fewer active metabolites and therefore a more predictable concentration-effect relationship, and a flat fixed-dose regimen instead of level-guided titration. In lupus nephritis it also has a direct podocyte-stabilising effect through inhibition of synaptopodin degradation, which contributes to proteinuria reduction independently of immunosuppression.

Targets: Cyclophilin A, Calcineurin, NFAT, Podocyte synaptopodin

• · Three 7.9 mg capsules twice daily, used on top of mycophenolate and low-dose steroids - it is an add-on, not a monotherapy.
• · The label specifies dose reduction based on eGFR decline from baseline - 7.9 mg or 15.8 mg twice daily depending on the magnitude of the fall.

Work out your exact syringe units →

• very commonReduced eGFR— Usually an early, partly reversible haemodynamic effect, but it drives the dose-reduction rules.
• very commonHypertension— Common enough that blood pressure is checked at every visit.
• commonDiarrhoea and abdominal pain
• commonHeadache
• commonAnaemia
• uncommonSerious infection— Carries a boxed warning for malignancy and serious infection risk, like other calcineurin inhibitors.
• rareMalignancy, particularly lymphoma and skin cancer— Class effect of chronic immunosuppression; boxed warning.

• Concurrent strong CYP3A4 inhibitors such as ketoconazole or clarithromycin - contraindicated on the label.
• eGFR below 45 mL/min/1.73 m2 unless benefit clearly outweighs risk.
• Active serious infection.
• Pregnancy - the mycophenolate it is used with is a known teratogen and effective contraception is required.

• conflictStrong CYP3A4 inhibitors — Contraindicated; exposure rises to dangerous levels.
• conflictStrong CYP3A4 inducers — Contraindicated; loss of efficacy.
• synergyMycophenolate mofetil — This is the intended combination - the trials tested voclosporin added on top of MMF and steroids.
• cautionNSAIDs — Additive renal risk.

• · eGFR at baseline, every two weeks for the first month, then monthly.
• · Blood pressure at every visit.
• · Serum potassium.
• · Urine protein-creatinine ratio as the efficacy endpoint.

FDA approved (Lupkynis) and EMA approved for lupus nephritis; prescription only.

• AURORA 1: voclosporin for lupus nephritis, phase 3 randomised trial (Lancet 2021) (trial)
• AURORA 2 continuation study of voclosporin in lupus nephritis (trial)
• Lupkynis (voclosporin) US prescribing information (label)

Two things distinguish voclosporin from its parent, and only one of them is about immunosuppression. The immunological mechanism is identical in kind: cyclophilin binding, calcineurin inhibition, NFAT retention in the cytoplasm, IL-2 transcription blocked. The difference is quantitative - roughly fourfold greater potency at the calcineurin target, meaning equivalent immunosuppression at lower exposure. The genuinely interesting mechanism is non-immunological. Calcineurin dephosphorylates synaptopodin in podocytes, and dephosphorylated synaptopodin is degraded by cathepsin L; synaptopodin is what maintains the podocyte actin cytoskeleton and therefore the integrity of the glomerular filtration barrier. Inhibiting calcineurin stabilises synaptopodin, stabilises the podocyte foot processes, and reduces proteinuria directly - independent of any effect on T-cells. That is why calcineurin inhibitors reduce proteinuria in conditions where the driver is not primarily immunological, and it is a real contributor to the AURORA 1 result rather than a mechanistic footnote. It also means the drug can improve the measured endpoint faster than immunosuppression alone would explain. The dosing consequence of the metabolite profile deserves emphasis: cyclosporine requires trough monitoring because active metabolites and erratic absorption decouple dose from effect; voclosporin does not, because they do not. A flat 23.7 mg twice daily with no blood levels is the single biggest practical advance this molecule represents.

The characteristic problem is the eGFR fall, and the trap is misreading it. An early drop is expected and largely reflects reversible afferent arteriolar vasoconstriction rather than structural injury, so panicking and stopping prematurely costs the patient a working drug. But there is no blood level to reassure you, and calcineurin inhibitors do cause irreversible chronic nephrotoxicity, so the label's percentage-based reduction rules are the substitute for monitoring and they need following literally rather than by clinical impression. The second issue is the flat-dosing double edge: no monitoring is a genuine convenience until a patient starts a strong CYP3A4 inhibitor, at which point exposure rises sharply and nothing catches it. That is why those agents are contraindicated rather than cautioned. Third, infection and malignancy - this is triple immunosuppression with a boxed warning, in a population that is already immunologically compromised by lupus. Fever on this regimen is not something to watch. Fourth, the practical one: three capsules twice daily on an empty stomach, twelve hours apart, is a demanding schedule, and taking it with food quietly cuts Cmax by up to half.

1. 23.7 mgFrom initiation — 23.7 mg (three 7.9 mg capsules) twice daily, twelve hours apart, on an empty stomach. This is the full dose from day one - there is no upward ramp, and that is deliberate. The steps below are the label's downward adjustments, which is the only direction this drug moves.
2. 15.8 mgTriggered by eGFR falling below 60 with a 20-30 percent reduction from baseline — Reduce by 7.9 mg twice daily, i.e. to 15.8 mg twice daily. Also triggered by blood pressure above 165/105 or hyperkalaemia.
3. 7.9 mgTriggered by a further fall, or on reinitiation after discontinuation — 7.9 mg twice daily. If eGFR fell by 30 percent or more the drug is stopped entirely, and reinitiation at this dose is considered only once eGFR recovers to at least 80 percent of baseline.

• Cyclophilin A — Binds cyclophilin to form the active inhibitory complex, as cyclosporine does

  Formation of the calcineurin-inhibiting composite surface.

• Calcineurin (protein phosphatase 2B) — Approximately fourfold more potent than cyclosporine A in calcineurin inhibition assays

  Blocks NFAT dephosphorylation and nuclear translocation, shutting down IL-2 and the T-cell activation programme.

• Podocyte synaptopodin (via calcineurin) — Not applicable - downstream substrate protection

  Prevents calcineurin-mediated dephosphorylation and subsequent cathepsin L degradation of synaptopodin, stabilising the podocyte actin cytoskeleton and directly reducing proteinuria independent of immunosuppression.

• AURORA 1 Phase 3 · n=357 · 52 weeks · 2021

  Complete renal response at 52 weeks in active lupus nephritis, voclosporin 23.7 mg twice daily versus placebo, both on background mycophenolate mofetil and low-dose steroids. 41 percent versus 23 percent, odds ratio 2.65, p<0.0001. 179 voclosporin versus 178 placebo. This is the trial the approval rests on and it is a properly powered, clearly positive result.

• AURORA 2 Phase 3 continuation · 104 weeks · 2024

  Long-term safety and efficacy over a further 24 months of continuous therapy in AURORA 1 completers. Demonstrated durability of the renal response and no new safety signal with extended exposure - which matters because the obvious worry with any calcineurin inhibitor is cumulative nephrotoxicity over years.

Hours 1-4: peak concentration after a fasted dose. Days 5-6: steady state, given a 30-hour half-life. Weeks 2-4: the early eGFR fall appears if it is going to, which is why the label mandates fortnightly monitoring for the first month. Weeks 4-8: proteinuria begins to fall - faster than immunosuppression alone would explain, because of the podocyte synaptopodin mechanism. Week 24: partial renal response becomes assessable. Week 52: the primary endpoint. Complete renal response at one year was 41 percent versus 23 percent on placebo. Years 1-2: AURORA 2 showed the response is durable and no new safety signal emerged over an additional 24 months.

Voclosporin is an add-on, not a monotherapy - every efficacy number quoted for it comes from trials where it was given on top of mycophenolate mofetil and low-dose glucocorticoids. Using it alone is off-evidence. Strong CYP3A4 inhibitors, including ketoconazole and clarithromycin, are contraindicated on the label rather than merely cautioned, because exposure rises to dangerous levels and there is no trough monitoring to catch it - which is the hidden cost of flat dosing. Strong inducers are equally contraindicated for loss of efficacy. NSAIDs add renal risk on top of a drug whose dose is governed by eGFR. Mycophenolate is a known teratogen, so effective contraception is a requirement of the regimen rather than a suggestion. Within this class, combining voclosporin with any thymic peptide or immunostimulant is incoherent - the entire point of the drug is to suppress the T-cell response those compounds exist to enhance.

The comparison that matters is against its own parent. Voclosporin gives roughly fourfold greater calcineurin potency per unit exposure, produces largely inactive metabolites instead of cyclosporine's AM1 and AM9, and is therefore dosed flat at 23.7 mg twice daily with no whole-blood trough monitoring - which removes the single most burdensome feature of calcineurin inhibitor therapy. It also has a defined, protocolised dose-reduction algorithm keyed to eGFR, which is a more honest way to manage nephrotoxicity than eyeballing a level. What it does not have is cyclosporine's forty years of real-world safety data, and cumulative nephrotoxicity over five or ten years is a genuinely open question that AURORA 2's two years cannot fully answer. Against mycophenolate alone in lupus nephritis, the AURORA 1 result is unambiguous - roughly double the complete renal response rate. Against belimumab, the other modern lupus nephritis addition, no head-to-head trial exists. Within this dataset, voclosporin and cyclosporine together are the reference standard for what properly evidenced peptide pharmacology looks like.

Deliberately null. Lupkynis is a specialty-tier branded product and real cost is determined almost entirely by insurance coverage, manufacturer assistance programmes and territory. No verified pricing was resolved in this session and inventing a figure would be worse than leaving it blank.

• ?Absolute oral bioavailability is not stated in the label and was not resolved elsewhere.
• ?The AURORA 2 participant number was not confirmed from an accessible abstract and is left null. The 104-week duration reflects the stated additional 24 months of continuation therapy.
• ?Blood-brain barrier penetration has not been characterised for voclosporin. It is marked unknown rather than assumed to match cyclosporine.
• ?The sequence field is marked unverified: the cyclosporine A backbone is well established, but the exact stereochemistry and structural detail of the amino acid-1 side chain modification were not confirmed against a primary structural source in this session.
• ?Cumulative nephrotoxicity beyond about three years of continuous exposure is not characterised. Two years of AURORA 2 data is reassuring but not definitive for a calcineurin inhibitor.
• ?Voclosporin has been studied almost exclusively in lupus nephritis on background mycophenolate. Its behaviour as monotherapy, or in other indications, is not established.
• ?The relative contribution of the podocyte synaptopodin mechanism versus immunosuppression to the proteinuria reduction seen in AURORA 1 has not been quantified.

• Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Rovin BH, Teng YKO, Ginzler EM, et al., Lancet, 2021 · PMID 33971155

  The pivotal trial. 357 patients, 52 weeks, complete renal response 41 versus 23 percent. Everything about the approval and the dosing derives from this.

• Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial Saxena A, Ginzler EM, Gibson K, et al., Arthritis & Rheumatology, 2024 · PMID 37466424

  The two-year continuation. Addresses the cumulative nephrotoxicity question that any calcineurin inhibitor has to answer.

• Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis Arriens C, Teng YKO, Ginzler EM, et al., Arthritis Care & Research, 2023 · PMID 36039949

  Pooled safety and efficacy across the development programme, which is the right place to look for adverse event rates rather than a single trial.

• LUPKYNIS (voclosporin) capsules - US prescribing information Aurinia Pharmaceuticals, FDA approved product labeling (accessed via openFDA)

  Source of the pharmacokinetics quoted here: tmax 1.5 h fasted, volume of distribution 2,154 L, clearance 63.6 L/h, protein binding 97 percent, half-life approximately 30 hours (24.9-36.5), CYP3A4 metabolism, 92.7 percent faecal and 2.1 percent urinary recovery, the food effect, the eGFR-triggered dose reductions and the boxed warning.

• Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the AURA-LV and AURORA studies Dall'Era M, Solomons N, Federico R, Truman M, Lupus, 2019 · PMID 31066646

  Context for the background regimen the trials used, which matters because voclosporin was never tested as monotherapy.